The mesenchymoangioblast, mesodermal precursor for mesenchymal and endothelial cells

Abstract

Mesenchymoangioblast (MB) is the earliest precursor for endothelial and mesenchymal cells originating from APLNRPDGFRαKDR mesoderm in human pluripotent stem cell cultures. MBs are identified based on their capacity to form FGF2-dependent compact spheroid colonies in a serum-free semisolid medium. MBs colonies are composed of PDGFRβCD271EMCNDLK1CD73 primitive mesenchymal cells which are generated through endothelial/angioblastic intermediates (cores) formed during first 3-4 days of clonogenic cultures. MB-derived primitive mesenchymal cells have potential to differentiate into mesenchymal stromal/stem cells (MSCs), pericytes, and smooth muscle cells. In this review, we summarize the specification and developmental potential of MBs, emphasize features that distinguish MBs from other mesenchymal progenitors described in the literature and discuss the value of these findings for identifying molecular pathways leading to MSC and vasculogenic cell specification, and developing cellular therapies using MB-derived progeny.

CD146+CD107a+ Mesenchymal Stem/Stromal Cells with Signature Attributes Correlate to Therapeutic Potency as “First Responders” to Injury and Inflammation

“…These include descriptions of their developmental origins (Corselli et al, 2010;Maijenburg et al, 2012;Sacchetti et al, 2016;Slukvin and Kumar, 2018), association with the perivascular niche (Corselli et al, 2013b;2013a;Covas et al, 2008;Crisan et al, 2008;Espagnolle et al, 2014;Tormin et al, 2011), self-renewal and stem-like capacities supporting hematopoiesis (Mendelson and Frenette, 2014b;Méndez-Ferrer et al, 2010;Sacchetti et al, 2016; and therapeutic use as osteoblastic progenitors for bone repair (James et al, 2017;2012). Our results further support this emerging distinction, now beyond those progenitor and hematopoietic support contributions for the CD146 + (POS) subpopulation.…”

Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study

“…1. This new production platform generates MSCs from iPSCs via an apelin receptor + lateral plate mesoderm intermediate cell with fibroblast growth factor-2 (FGF2)-dependent colony-forming potential, known as an MCA 20,21 . This approach allows for the production of well-defined MSCs that express lateral plate, but not paraxial or intermediate, mesoderm markers.…”

Cellular and Molecular Mechanisms of Environmental Pollutants on Hematopoiesis

“…EPCs are recruited in response to ischemia and initiate angiogenesis, leading to the formation of new blood vessels, connecting fibronectin, and forming colonies and/or colony-forming units [ 37 , 38 ]. EPCs resemble embryonic angioblasts, which are anchorage-independent cells capable of proliferating, migrating, and differentiating into mature ECs [ 39 ]. EPCs express mainly cluster of differentiation 34 (CD34) and fetal liver kinase 1 (FLK1), although other markers have also already been identified, such as vascular endothelial growth factor receptor 2 (VEGFR2) and CD146 [ 40 ].…”